Analyst Salveen Richter from Goldman Sachs maintained a Buy rating on Alnylam Pharma and keeping the price target at $566.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Salveen Richter has given his Buy rating due to a combination of factors including Alnylam Pharmaceuticals’ strong performance in the market and the promising results from their Amvuttra product. The company’s transition to non-GAAP profitability and its outperformance compared to both the sector and broader markets have been significant contributors to this positive outlook.
Richter also highlights the potential for Alnylam’s TTR amyloidosis treatment to exceed revenue expectations, driven by favorable script trends. Moreover, the company’s pipeline, including assets in Huntington’s disease and other disorders, adds to the growth potential. The focus on maintaining launch momentum and expanding market penetration further supports the Buy rating, alongside the anticipation of new strategic goals to be disclosed in the near future.
In another report released yesterday, Bernstein also maintained a Buy rating on the stock with a $471.00 price target.
ALNY’s price has also changed dramatically for the past six months – from $242.610 to $463.430, which is a 91.02% increase.